Flotillin microdomains, specialized lipid raft domains in cell membranes, serve as physical platforms for many different molecules important in crucial intracellular signaling pathways. Flotillin-2 (Flot2), together with flotillin-1, is a marker for lipid raft microdomains distinct from caveolar lipid rafts, and has been implicated in the progression of cancer and metastasis formation. Based largely on studies in xenograft models, flotillin-2 has been implicated in the progression of multiple types of human tumors, including breast cancer. In our studies, we identified flotillin-2 as highly amplified in a high-throughput comparative genomic hybridization screen of human breast cancer cell lines and breast tumor samples. Short hairpin RNA-mediated reduction of flotillin-2 protein levels significantly reduced the tumorigenicity and metastatic capability of a human breast cancer cell line in vivo. We generated mice deficient for flotillin-2 and also found a reduction of flotillin-1 protein levels and complete absence of flotillin-specific membrane microdomains in these mice. To examine the role of Flot2 in mammary tumorigenesis and lung metastasis, we used an in vivo molecular genetics approach, crossing a well-characterized transgenic mouse model of breast cancer, the MMTV-PyMT (mouse mammary tumor virus-polyoma middle T antigen) mouse, with gene-targeted Flot2
INTRODUCTION
Breast cancer is the most frequently diagnosed cancer in women worldwide, and metastatic breast cancer is the leading cause of death from cancer among women globally. 1 The most frequent sites of breast cancer metastasis are bone, lung, liver and brain. Both breast cancer progression and metastasis formation depend in part on abnormalities of lipid rafts, due to their crucial role in a number of cellular mechanisms that are dysregulated in breast tumor cells, such as altered protein signaling and trafficking. 2 Lipid rafts are plasma membrane microdomains that are highly enriched in cholesterol and glycosphingolipids, 3, 4 and serve as platforms for many crucial intracellular signaling proteins. 2 Two different types of lipid rafts exist: the caveolae, which are highly enriched in proteins from the caveolin family, 5, 6 and non-caveolar lipid rafts, which are characterized by their expression of flotillin-1 and flotillin-2, Flot2 (also known as reggie-2 and reggie-1, respectively 7 ). Flotillins were initially thought to be associated with caveolae, 8 but it was later shown that lipid rafts containing flotillin microdomains were distinct from caveolae. 9, 10 The signaling pathways associated with both types of lipid rafts are altered in various kinds of cancer cells. 11, 12 In particular, the formation of invadopodia, which are membrane protrusions important for extracellular matrix penetration, depends on lipid rafts, 13 and lipid rafts are concentrated in the leading edge of breast cancer cell invadopodia.
14 Flotillin-1 expression correlates with increasing grade in human breast cancer samples, 15 and knockdown of flotillin-1 impairs breast cancer cell proliferation and tumorigenicity. 15 Enhanced Flot2 expression is associated with melanoma progression in humans 16 and with metastasis formation in human head and neck squamous cell carcinomas. 17 In mouse xenografts, Flot2 overexpression has been reported to drive the transformation of a non-tumorigenic, non-metastatic melanoma cell line (SB2) into a highly tumorigenic, metastatic cell line. 16 In cell cultures, Flot2 knockdown reduces cell spreading, whereas epidermal growth factor-dependent phosphorylation of Flot2 by Src kinase enhances cell spreading. 9 In this study, we performed a high-throughput comparative genomic hybridization screen of human breast cancer cell lines and breast tumor samples to identify genomic regions showing amplification across both. We found that the Flot2 gene encoding Flot2 was highly amplified in several breast cancer cell lines and breast tumor samples. On the basis of these findings and the reported association of Flot2 with breast tumorigenesis and metastasis, we employed two genetic approaches to investigate Figure 1 . Flot2 is essential for breast cancer cell proliferation in vivo. (a) Copy number alterations in a panel of 50 breast cancer cell lines (a kind gift from Dennis Slamon, UCLA, CA, USA) and 17 breast cancer tissues (a kind gift from Susan Done, UHN, ON, Canada) as assessed by array comparative genomic hybridization. Construction of the sub-megabase resolution tiling (SMRT) array used for these experiments is described in de Leeuw et al. 25 and Ishkanian et al., 26 and the methods are described in more detail in Watson et al. 27 The BAC clone containing Flot2 was within a longer 17q11.2 amplicon (human genome version hg17) and was amplified to levels greater than log2 ratio (tumor/normal) of 0.3 in four breast cancer tumor tissues and six breast cancer cell lines. In this panel, four patient samples harboring the Flot2 amplicon are shown in yellow. The Flot2 amplicon resides upstream from the Her2 amplicon (pink) and the HoxB amplicon (green) on chromosome 17. (b) Immunoblot confirmation of the stable short hairpin RNA-mediated knockdown of Flot2 in two independent MDA-MB-231-luc cell lines. Short hairpin RNAs against Flot2 were purchased ready for lentiviral expression from Open Biosystems Products (Huntsville, AL, USA). Lentiviral particles were produced in 293FT cells and virus-containing culture supernatants were used to infect cells in the presence of 8 g/ml polybrene (Sigma-Aldrich, Oakville, ON, Canada). Levels of flotillin-1 and Flot2 protein in whole-cell lysates of empty vector control cells (ev) and shFlot2-10 and shFlot2-12 cells 10, 12 were determined using primary mouse anti-flotillin-1 and anti-Flot2 monoclonal antibodies (both from BD Transduction Laboratories, Mississauga, ON, Canada). Actin (loading control) was detected using rabbit anti-actin antibody (Sigma-Aldrich, Oakville, ON, Canada). Bands were visualized using the appropriate secondary antibodies and enhanced chemiluminescence (ECL-kit, Amersham Biosciences, Piscataway, NJ, USA) according to the manufacturer's recommendations. (c-e) Knockdown of Flot2 inhibits the tumorigenicity of breast cancer cells in vivo. The mammary fat pads of athymic nude NIH-III mice were xenografted with shFlot2-10 (n ¼ 9), shFlot2-12 (n ¼ 9), or empty vector control, (n 5 in 100 ml phosphate-buffered saline) were injected into the tail veins of severe combined immunodefecient mice (n ¼ 8/group). In situ imaging of engrafted cells at 19 days post injection was performed using a Xenogen apparatus (IVIS Imaging Systems, Caliper LifeSciences, Hopkinton, MA, USA). (g) Survival of the mice in (g) over 40-50 days was evaluated using Kaplan-Meier methodology. All animal experiments were approved by the Animal Care Committee of the University Health Network (Toronto, ON, Canada). For c, d, the data were analyzed using the Student's t-test and are presented as the mean ± s.d. Values of Po0.05 were considered statistically significant; **Po0.01, ***Po0.001. For g, the data were analyzed using the log-rank test; *Po0.05. 18 Our results point to a crucial function for Flot2 in the metastasis of breast cancer cells.
RESULTS AND DISCUSSION
We performed a comparative genomic hybridization screen of 17 human breast cancer samples and 50 human breast cancer cell lines and identified Flot2 as being located in a region on human chromosome 17q11.2 that is commonly amplified in human breast cancers. Use of the MultiExperiment Viewer version 4.8 (MeV) 19, 20 to examine the Flot2 amplicon in breast cancer tissues in the context of other genomic aberrations on chromosome 17 showed that although the Flot2 amplicon is upstream of both the Her2 and HoxB amplicons, it is an independent genomic aberration, with large regions of non-amplified DNA separating the duplication events ( Figure 1a) .
To investigate the role of Flot2 in the tumorigenic activity of breast cancer cells, we generated two stable Flot2 knockdown MDA-MB-231-luc cell lines, designated shFlot2-10 and shFlot2-12 ( Figure 1b) . The proliferation of these cells in vitro was not inhibited by their lack of Flot2 (Supplementary Figure S1) , in contrast to the reported poor proliferation of flotillin-1 knockdown breast cancer cells. 15 To determine whether Flot2 depletion had an effect on the tumorigenicity of breast cancer cells in vivo, we xenografted wild-type (WT) MDA-MB-231-luc cells, or shFlot2-10 or shFlot2-12 MDA-MB-231-luc cells, into the mammary fat pads of athymic NIH-III nude mice. As shown in Figures 1c-e, total tumor volumes and weights were significantly reduced in mice bearing Flot2-depleted MDA-MB-231-luc cells compared with mice bearing WT MDA-MB-231-luc cells. These results indicate that Flot2 indeed is required for breast tumorigenesis in vivo.
We next tested the ability of Flot2 knockdown cells to survive in the circulation and extravasate into the stroma of the lung and form metastases. WT MDA-MB-231-luc cells, or shFlot2-10 or shFlot2-12 MDA-MB-231-luc cells, were injected intravenously into the tail veins of severe combined immunodefecient mice. Mouse survival was monitored and engraftment of tumor cells into the lungs was evaluated by xenogen imaging. After 19 days, mice engrafted with WT MDA-MB-231-luc cells showed a strong accumulation of tumor cells in the lungs, whereas mice engrafted with shFlot2-10 MDA-MB-231-luc cells showed barely detectable lung engraftment (Figure 1f) . As a consequence, mice injected with shFlot2-10 MDA-MB-231-luc or shFlot2-12 MDA-MB-231-luc cells had significantly increased lifespans (about 44 days) compared twith mice that had been engrafted with WT MDA-MB-231-luc cells (about 36 days; Figure 1g , log-rank test, Po0.05). Thus, mice engrafted with breast cancer cells in which Flot2 expression is substantially depleted show delayed lung metastasis formation.
To be able to utilize mouse mammary tumorigenesis models that better reflect the complex multistage nature of human tumorigenesis, we used homologous recombination in mouse embryonic stem (ES) cells to disrupt the Flot2 gene and generate Flot2
À / À knockout mice completely lacking Flot2 protein expression (Supplementary Figure S2a) . The targeting vector was designed to replace most of the Flot2 coding region, including exons 3-10, with the PGK-neo cassette. We obtained 13 independent ES cell clones carrying the mutated Flot2 allele, and Southern blot analysis of their DNA hybridized to a 3 0 flanking probe or a neomycin-specific probe confirmed a single integration (Supplementary Figure S2b) . Four correctly targeted ES cell clones were injected (separately) into C57BL/6J blastocysts to generate chimeric mice. F1 heterozygote mice originating from one clone were intercrossed to produce the Flot2 þ / þ and Flot2 À / À F2 progeny analyzed in this report. Immunoblotting of extracts of mouse embryonic fibroblasts (MEFs) prepared from Flot2 þ / þ and Flot2 À / À littermate mice confirmed that the knockout Flot2 allele was a null mutation, and that no Flot2 protein was detectable in these cells (Figure 2a) .
Interestingly, the expression of flotillin-1 protein was also reduced in Flot2 À / À MEFs (Figure 2a) , a finding confirmed in several organs of these mutants (Figure 2b ). These results are in accordance with a previous report showing that genetic ablation of flotillin-1 concomitantly reduces Flot2 expression, 21 but are in contrast to our results obtained with short hairpin RNA-mediated Flot2 protein reduction, where we did not observe a significant flotillin-1 protein level decrease. It is feasible that although both flotillin-1 and -2 are necessary for the formation of flotillin membrane microdomains, the residual amount of Flot2 still present in the Flot2 knockdown MDA-MB-231-luc cell lines is sufficient to stabilize flotillin-1 and prevent its degradation. þ / þ and Flot2 À / À MEFs by fractionation using detergent resistant membranes (DRM) floatation sucrose densitygradient centrifugation as previously described. 21 Fractions including membranes (fractions 8-10, boxed) were analyzed by immunoblotting to detect (c) flotillin-1 and (d) caveolin-1 using specific primary antibodies from Santa Cruz Biotechnology, (Santa Cruz, CA, USA). Briefly, cell pellets were resuspended in 1 ml ice-cold TNE buffer (50 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA) containing a protease inhibitor cocktail (Roche Canada, Laval, QC, Canada), and 1 ml icecold 2% Triton X-100 in TNE was added for a 30 min incubation on ice. After pelleting of nuclei by centrifugation at 1000 g for 5 min, 2 ml 80% sucrose in TNE was added to adjust the lysate to 40% sucrose. The lysate was pipetted into the bottom of an ultracentrifuge tube (Beckman Instruments, Palo Alto, CA, USA), and 6 ml 35% sucrose and then 2 ml 5% sucrose (both in TNE) were carefully layered on top. The gradient was centrifuged at 30 000 r.p.m. (SW40 rotor, Beckman Coulter, Mississauga, ON, Canada) for 20.6 h. Twelve 1 ml fractions were collected (starting from the bottom) by tube puncture and proteins were precipitated using MeOH/CHCl 3 .
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Lipid rafts are insoluble in cold non-ionic detergents, 8 which offers a means of isolating them. We prepared cold Triton X-100-solubilized extracts of Flot2 þ / þ and Flot2 À / À MEFs and subjected them to sucrose density-gradient ultracentrifugation. Consistent with our previous finding, no residual flotillin-1 protein was detected in the detergent-resistant fractions of the mutant extracts (Figure 2c ). In contrast, the distribution of caveolin was not altered in fractionated extracts of Flot2 À / À MEFs (Figure 2d ). These results indicate that a complete ablation of Flot2 abolishes the formation of functional flotillin, but not caveolar membrane microdomains.
To analyze the role of Flot2 in tumor initiation, progression and metastasis, we took advantage of the MMTV-PyMT mouse model of mammary tumorigenesis. WT female MMTV-PyMT mice develop multifocal dysplastic atypia in the mammary epithelium as early as 3 weeks after birth. These lesions are thought to be the origin of the primary mammary adenocarcinomas that appear in these animals with an average latency of about 35-40 days. 18 Thereafter, these primary tumors spontaneously metastasize to the lungs with a high penetrance. The relevance of the MMTV-PyMT model to human breast cancer has been validated by both genetic and histological studies, 22, 23 and the stages of tumorigenesis in MMTVPyMT mice demonstrate a striking similarity to the stages of human ductal adenocarcinogenesis. In particular, both ErbB2/Neu and cyclin D1 expression are upregulated in MMTV-PyMT tumor cells, just as that occurs in human ductal adenocarcinoma cells. 22, 24 To test whether Flot2 is an oncogene contributing to the formation of mammary tumors in the MMTV-PyMT model, we generated Flot2
MMTV-PyMT (Flot2 À / À PyMT) mice and compared spontaneous tumor formation and metastasis in female animals. Both Flot2 À / À PyMT (n ¼ 28) and Flot2 þ / þ PyMT (n ¼ 26) mice were killed at about 160 days after birth (Figure 3a) , a time point shortly before the tumor burdens in both strains of mice reached the humane end point. We analyzed numbers of mammary glands bearing tumors (as assessed by gross histological analysis), the total volume of all mammary tumors per animal, and the total wet weight of all mammary tumors per animal, but no significant differences were detected (Figures 3b-d) . These data indicate that a lack of Flot2 does not interfere with overall primary tumor formation in MMTV-PyMT mice.
A great advantage of the MMTV-PyMT mouse model is that it can be seamlessly used to study both primary mammary tumor development and metastasis. A high percentage of MMTV-PyMT mice develop metastases in the lungs, and these lesions can be readily observed macroscopically and microscopically. 18 To determine whether Flot2 influences metastasis formation, we examined the lungs of Flot2 þ / þ PyMT and Flot2 À / À PyMT mice at the time of killing (160 days). Upon gross observation to detect surface lesions, we found that the lungs of Flot2 À / À PyMT mice exhibited 10-fold fewer visible macro-metastases compared with the lungs of Flot2 þ / þ PyMT controls (2.1 ± 1.1 vs 21.7 ± 7.2; Figure 3e ). We then prepared a minimum of five lung tissue sections (200 mm apart) per lung, stained them with hematoxylineosin, and counted numbers of visible micro-metastases. Again, there was a significant decrease in the number of (Figure 4a ). These cells (or their control counterparts) were then xenografted into the mammary fat pads of NIH-III nude mice (n ¼ 11/13 per group). By 50 days post injection, the total wet weight of tumors arising from the Flot2 À / À PyMT cell line was equivalent to the total wet weight of tumors arising from the Flot2 þ / þ PyMT cell line (3.5 ± 0.4 vs 2.5 ± 0.3 g; Figure 4b ).
Importantly, however, the number of macro-metastases visible on the lungs of NIH-III mice engrafted with Flot2 À / À PyMT cells was significantly reduced compared with mice engrafted with Flot2 þ / þ PyMT cells (0.9±0.7 vs 6.4±1.4; Figure 4c ). Furthermore, the number of lung micro-metastases detectable by hematoxylin-eosin staining was five-fold lower in NIH-III mice that had been engrafted with Flot2 À / À PyMT cells compared with those engrafted with Flot2 þ / þ PyMT cells (4.2±2.6 vs 20.1 ± 4.5; Figure 4d) .
The results of our experiments using genetic ablation of Flot2 and a well-established mouse model of mammary tumorigenesis and metastasis show for the first time that Flot2 has an important role in regulating breast cancer-derived lung metastasis formation. These data confirm previously reported findings associating Flot2 with metastasis formation in human head and neck squamous cell carcinomas 17 and the transformation of a non-metastatic melanoma cell line into a metastatic cell line, 16 and underline the importance of future research into the function of flotillin microdomains in cancer progression and metastasis formation. PyMT mice using a previously described protocol. 28 The immunoblot analysis of the corresponding 
